Zelnick Kaufman, chief legal officer at CorMedix, sells $670k in shares

Beth Zelnick Kaufman, Chief Legal Officer of CorMedix Inc (NASDAQ:CRMD), a company that has delivered a remarkable 90% return over the past year and maintains a GREAT financial health score according to InvestingPro, sold 50,000 shares of common stock on September 9, 2025. The sales, executed in two transactions, totaled $670,264. The price range for the shares sold was between $12.82 and $13.41, with the current market cap at $982 million. Analysis from InvestingPro suggests the stock is currently trading below its Fair Value.

On the same day, Zelnick Kaufman also exercised options to acquire 50,000 shares of CorMedix common stock at an exercise price of $3.30, for a total value of $165,000.

Following these transactions, Zelnick Kaufman directly owns 180,418 shares of CorMedix Inc .

In other recent news, CorMedix Inc. has completed a $150 million convertible notes offering, with the notes due in 2030. The company also announced a definitive agreement to acquire Melinta Therapeutics LLC for $300 million, which will add seven drug products to its portfolio. This acquisition involves a $260 million cash payment and $40 million in equity, with potential milestone payments and royalties. Additionally, CorMedix led a $29 million financing round in Talphera, Inc., with an initial closing of $17 million expected soon. The investment provides CorMedix an exclusive negotiation right to acquire Talphera after Phase 3 results for its lead candidate, Niyad. Analyst firm JMP Securities reiterated its Market Outperform rating for CorMedix, maintaining a price target of $22. Meanwhile, D. Boral Capital downgraded CorMedix’s stock rating from Buy to Hold following a public offering announcement expected to raise $85 million. These developments indicate significant strategic moves by CorMedix in recent times.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.